X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Week in Review: The latest from PhRMA

By Priscilla VanderVeer  |    January 29, 2016
Record number of new medicines in 2015: The FDA’s Center for Drug Evaluation and Research’s (CDER) fifth annual Novel New Drugs Summary approved a record 45 new medicines in 2015, marking the...   Read More

Medicare Monday: Drug coverage before and after Medicare Part D

By Allyson Funk  |    January 25, 2016
A couple of weeks ago, we talked about the success of the Medicare prescription drug program 10 years after its implementation, and over the coming weeks, we’ll continue to look at coverage before...   Read More

2015: A banner year for personalized medicine

By Emma Van Hook  |    January 22, 2016
2015 was a record year for personalized medicine approvals, according to a new analysis  from the Personalized Medicine Coalition (PMC). This news confirms the growing role of personalized...   Read More

PhRMA and BIO Citizen Petition to FDA calls for biosimilar labeling guidance

By Jeff Francer  |    January 21, 2016
Biosimilars will continue to become more widely available to patients in 2016 and beyond.  PhRMA supports science-based regulation of biosimilars by the Food and Drug Administration (FDA)....   Read More

PPA: More than just prescription assistance

By Ieva M. Augstums  |    January 19, 2016
Since its launch in 2005, the Partnership for Prescription Assistance – or PPA – has helped connect nearly 9.5 million people with public and private patient assistance programs. A nationwide...   Read More

ICYMI: American Society for Clinical Oncology statement on clinical pathways

By Kelsey Lang  |    January 18, 2016
Last week, the American Society for Clinical Oncology (ASCO) issued a policy statement calling for improvements in clinical pathway programs. The statement responds to the growing concern that...   Read More

Medicare Monday: 3 things to know about Medicare Part B

By Allyson Funk  |    January 18, 2016
Last week we talked about 3 reasons why Medicare Part D is a success. This week, we’re switching gears to talk about Medicare Part B. Here are 3 things to know about Medicare Part B: The Medicare...   Read More

Do you know how insurance covers your medicines?

By Allyson Funk  |    January 14, 2016
You’ve seen our check lists of questions to ask about your insurance coverage and how to make sure your medicines are covered, but do you know how (and if) your insurance plan covers your...   Read More

Biopharmaceutical industry has made progress in cancer fight, continues work toward moonshot

By Stephen J. Ubl  |    January 13, 2016
Yesterday, in his final State of the Union Address, President Barack Obama endorsed Vice President Joe Biden’s call for a moonshot to cure cancer by 2020. Making advances in cancer care and...   Read More

FDA approves a record 45 new medicines in 2015

By Holly Campbell  |    January 11, 2016
Last year was an exceptionally strong year for biopharmaceutical innovation as the U.S. Food and Drug Administration (FDA) approved 45 new medicines – the highest number of approvals in almost two...   Read More

Medicare Monday: 10 years later, 3 reasons why Part D is a success story

By Allyson Funk  |    January 11, 2016
January 2016 marks the 10th anniversary of the implementation of Medicare Part D. Medicare’s prescription drug benefit was created in 2003 and first implemented 10 years ago so we’re sharing three...   Read More

Week in review: The latest from PhRMA

By Priscilla VanderVeer  |    January 8, 2016
Rising deductibles and out-of-pocket costs:  A new Kaiser Family Foundation/New York Times survey outlined the challenges Americans, even those with insurance, are having with medical bills. The...   Read More

What they are saying: Rising deductibles and out-of-pocket costs in health insurance plans

By Allyson Funk  |    January 6, 2016
Many consumers are facing higher deductibles and cost sharing – including for services likes prescription medicines – that create barriers to accessing needed care. And a new Kaiser Family...   Read More

Medicare Monday: Goodbye 2015, hello 2016!

By Allyson Funk  |    January 4, 2016
Welcome back to Medicare Monday where we have a lot of exciting things planned for 2016. Did you know that 2016 marks the 10th anniversary of the implementation of Medicare Part D? We’ll be...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Most Popular Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."